TregTherapeutics Inc. is a preclinical stage company focused on the treatment and cure of multiple sclerosis. The objective of the TregTherapeutics tolerogenic vaccine is to reverse the inflammatory T cell immune attack in demyelinating lesions of an MS patient, and subsequently, to create an anti-inflammatory tolerogenic response within that patient.
View Top Employees from TregTherapeutics Inc.| Website | http://www.tregtherapeutics.com |
| Revenue | $5.8 million |
| Employees | 3 (1 on RocketReach) |
| Founded | 2018 |
| Address | 183 Dark Forest Dr, Chapel Hill, North Carolina 27516, US |
| Industry | Biotechnology Research, Chemicals, Petrochemicals, Glass & Gases, Biotechnology, Manufacturing, Science and Engineering, Clinical Trials, Health Care |
| Competitors | AltruBio Inc., Immunomic Therapeutics, Inc. |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325414 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular TregTherapeutics Inc. employee's phone or email?
TregTherapeutics Inc. Questions
The TregTherapeutics Inc. annual revenue was $5.8 million in 2024.
Russell Bromley is the President of TregTherapeutics Inc..
1 people are employed at TregTherapeutics Inc..
TregTherapeutics Inc. is based in Chapel Hill, North Carolina.
The NAICS codes for TregTherapeutics Inc. are [325414, 32, 3254, 32541, 325].
The SIC codes for TregTherapeutics Inc. are [28, 283].
Top TregTherapeutics Inc. Employees
Related Companies
